Closed-loop artificial pancreas from Tandem, Dexcom aces Type 1 diabetes study

A clinical trial of an artificial pancreas system showed it was able to outperform current treatments for people with Type 1 diabetes and help maintain blood sugar levels throughout the day as well as overnight.a

By linking Tandem Diabetes Care’s T:slim X2 alternate controller-enabled insulin pump with Dexcom’s G6 continuous glucose monitor (CGM), the closed-loop system automatically delivers the hormone based on blood sugar readings and other data without the need for fingerstick draws or daily injections.

The six-month trial—part of a series within the National Institutes of Health (NIH)-funded International Diabetes Closed-Loop study—enrolled 168 participants age 14 and older and followed them in real-world settings. They received either the artificial pancreas system, dubbed Control-IQ, or a sensor-augmented pump and CGM combination that did not automatically adjust insulin delivery.

The Control-IQ system was better at helping participants keep their glucose levels within a healthy range—by an average of 2.6 hours per day compared to the start of the study—while the control group showed no gains in time.

More here –>

Print Friendly, PDF & Email